Combination therapy comprising JAK pathway inhibitor and rock inhibitor
US11918581B2 · kind B2 · utility
0Cited by
11References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 10, 2022 |
| Grant date | Mar 5, 2024 |
| Priority date | — |
| Expiry date | Jan 10, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.